GSK’s bid for Human Genome Sciences rejected

GlaxoSmithKline has launched a takeover bid for Human Genome Sciences for around $2.5 billion, but has been rejected by the US-based firm. GSK and HGS launched their co-developed lupus treatment Benly…
Read the full story: InPharm